Emerging Therapies in Melanoma

Clinical Advances in Hematology & Oncology November 2012, Volume 10, Issue 11 H&O What are the current outcomes in melanoma, and how are the data evolving? […]

PD-1–Targeted Immunotherapy: Recent Clinical Findings

Julie R. Brahmer, MD Associate Professor of Medical Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland H&O What is known about the role […]

Scarcity of Vital Oncology Drugs: Finding Long-Term Solutions

Richard L. Schilsky, MD Immediate Past Chair Government Relations Committee, ASCO Professor of Medicine Chief, Section of Hematology-Oncology The University of Chicago Medicine Chicago, Illinois H&O […]

Using Ligands to Target Cancer Cells

Omid C. Farokhzad, MD Associate Professor of Anesthesia Harvard Medical School Director, Laboratory of Nanomedicine and Biomaterials Brigham and Women’s Hospital Boston, Massachusetts H&O What are […]

Clinical Applications of Next-Generation Sequencing

Michiaki Kubo, MD, PhD Acting Director RIKEN Center for Genomic Medicine Yokohama, Kanagawa Japan H&O What is next-generation sequencing (NGS)? MK NGS (also known as second-generation […]

Importance of Food Effects for Oral Oncology Drugs

Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics Associate Director for Clinical Sciences Comprehensive Cancer Center The University of […]

PARP Inhibitors

Ruth Plummer, MA, BMBCh, DPhil, MD, FRCP Professor of Experimental Cancer Medicine Northern Institute for Cancer Research Newcastle University Newcastle upon Tyne, United Kingdom H&O What […]

New Approaches to Thyroid Cancer

Ezra E. Cohen, MD Associate Professor of Medicine Associate Director for Education University of Chicago Comprehensive Cancer Center Chicago, Illinois H&O How common is thyroid cancer, […]

Abiraterone: Current and FutureUse in Prostate Cancer

Charles J. Ryan, MD Associate Professor of Medicine and Urology Program Leader, Genitourinary Medical Oncology UCSF Helen Diller Family Comprehensive Cancer San Francisco, California H&O What […]

The Generic Drug Shortage

George Tidmarsh, MD, PhD Citizen’s Oncology Foundation Consulting Associate Professor of Pediatrics/Neonatology Stanford University School of Medicine Stanford, California H&O What are some of the issues […]

Harnessing the Immune Response

Thomas Gajewski, MD, PhD Professor, Department of Pathology and Department of Medicine Section of Hematology/Oncology Chicago, Illinois H&O hat is immunotherapy? TG he idea behind immunotherapy is to […]

Diagnosis and Treatment of Atypical Hemolytic Uremic Syndrome

Catherine Broome, MD Associate Clinical Professor of Medicine Lombardi Cancer Center Georgetown University Hospital Washington, DC H&O What is atypical hemolytic uremic syndrome? CB Atypical hemolytic uremic syndrome […]

Advances in the Treatment of Neuroblastoma

Susan Cohn, MD Professor of Pediatrics Director, Clinical Research Section of Pediatric Hematology/Oncology Comer Children’s Hospital The University of Chicago Chicago, Illinois H&O What is the treatment […]

Cancer Vaccines

Yusuke Nakamura, MD, PhD Professor, Laboratory of Molecular Medicine Institute of Medical Science The University of Tokyo Tokyo, Japan H&O What are some recent developments in tumor […]

Advances in Biomarkers for Targeted Agents

Advances in Biomarkers for Targeted Agents Michael L. Maitland, MD, PhD Assistant Professor of Medicine Section of Hematology/Oncology Associate Director, Committee on Clinical Pharmacology and Pharmacogenomics […]

Next Generation Clinical Trials

Donald A. Berry, PhD Professor, Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston, Texas H&O What is the current method that is used […]

Nilotinib Risk Evaluation and Mitigation Strategy

Maria Baer, MD Professor of Medicine University of Maryland School of Medicine Director, Hematologic Malignancies University of Maryland Greenebaum Cancer Center Baltimore, Maryland H&O Why does the […]

Off-Label Drug Utilization in Oncology

Jonas A. de Souza, MD Instructor of Medicine Section of Hematology/Oncology University of Chicago Medical Center Chicago, Illinois H&O What is the definition of off-label drug utilization? […]

Rationing Cancer Care: the Emerging Debate

Daniel Callahan, PhD Senior Research Scholar President Emeritus The Hastings Center Garrison, New York H&O Can you provide some background on the current state of cancer care […]

Current Dilemmas in Carboplatin Dosing

Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics Associate Director for Clinical Sciences Cancer Research Center The University of […]